AZD1208 is a novel, orally bioavailable, highly selective PIM kinases inhibitor with single nanomolar potency against all three PIM kinases and is currently undergoing Phase I testing and dose escalation studies in AML.

 June 21, 2017

prudect name : AZD1208 is a novel, orally bioavailable, highly selective PIM kinases inhibitor with single nanomolar potency against all three PIM kinases and is currently undergoing Phase I testing…

📌
0💬 read more

prudect name : AltrenogestSynonyms: CAS NO: 850-52-2Molecular Formula: C21H26O2Molecular Weight: 310.43Purity: 99% minSolubility: Storage: −20°C

prudect name : Altrenogest Synonyms: CAS NO: 850-52-2Molecular Formula: C21H26O2Molecular Weight: 310.43Purity: 99% minSolubility: Storage: −20°C 154229-19-3 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18502225

📌
0💬 read more

prudect name : Azelaic acidSynonyms: Nonanedioic acidCAS NO: 123-99-9Molecular Formula: C9H16O4Molecular Weight: 188.22Purity: 98% minSolubility:

prudect name : Azelaic acid Synonyms: Nonanedioic acidCAS NO: 123-99-9Molecular Formula: C9H16O4Molecular Weight: 188.22Purity: 98% minSolubility: in DMSOStorage: -20oC 1062243-51-9 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18502167

📌
0💬 read more

prudect name : AlprostadilSynonyms: CAS NO: 745-65-3Molecular Formula: C20H34O5Molecular Weight: 354.48Purity: 99%Solubility: Storage: −20°C

prudect name : Alprostadil Synonyms: CAS NO: 745-65-3Molecular Formula: C20H34O5Molecular Weight: 354.48Purity: 99%Solubility: Storage: −20°C 2 years 129496-10-2 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18502103

📌
0💬 read more

prudect name : AllylestrenolSynonyms: CAS NO: 432-60-0Molecular Formula: C21H32OMolecular Weight: 300.48Purity: 98% minSolubility: Storage: −20°C

prudect name : Allylestrenol Synonyms: CAS NO: 432-60-0Molecular Formula: C21H32OMolecular Weight: 300.48Purity: 98% minSolubility: Storage: −20°C 356559-20-1 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18502066

📌
0💬 read more

Amrubicin Hydrochloride is fully synthetic anthracycline anticancer drugs adriamycin class

prudect name : Amrubicin Hydrochloride is fully synthetic anthracycline anticancer drugs adriamycin classAmrubicin Hydrochloride Synonyms: CAS NO: 92470-31-0Molecular Formula: C25H25NO9.HCLMolecular Weight: 519.92Purity: ≥99%Solubility: In DMSOStorage: −20°C 2 years 1140909-48-3 References…

📌
0💬 read more

A-966492 is one of the most potent PARP inhibitors. A-966492 displays excellent potency against the PARP-1 enzyme with a Kiof 1 nM and an EC50 of 1 nM in a whole cell assay. A-966492 significantly enhances the efficacy of TMZ in a dose-dependent manner. In addition, A-966492 is orally bioavailable across multiple species, crosses the blood−brain barrier, and appears to distribute into tumor tissue. A-966492 represents a promising, structurally diverse benzimidazole analogue and is being further characterized preclinically.

prudect name : A-966492 is one of the most potent PARP inhibitors. A-966492 displays excellent potency against the PARP-1 enzyme with a Kiof 1 nM and an EC50 of 1…

📌
0💬 read more

prudect name : AltretamineSynonyms: CAS NO: 645-05-6Molecular Formula: C9H18N6Molecular Weight: 210.28Purity: 99%Solubility: Storage: −20°C

prudect name : Altretamine Synonyms: CAS NO: 645-05-6Molecular Formula: C9H18N6Molecular Weight: 210.28Purity: 99%Solubility: Storage: −20°C 2 years 215543-92-3 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18502001

📌
0💬 read more

ACTB-1003 is a potent inhibitor of FGFR1 with IC50 <10 nM in FGFR-1 biochemical assay; more information can be find in Patent WO/2007/064883A2, Example 12.

prudect name : ACTB-1003 is a potent inhibitor of FGFR1 with IC50

📌
0💬 read more

AGI-5198 (IDH-C35) is the first highly potent and selective mutant IDH1 inhibitor that was shown to have anti-tumor efficacy and lower tumor 2‑HG (2-hydroxyglutarate) in vivo. It inhibits IDH1 R132H mutant and R132C mutant in vitro with IC50 ~0.07 µM and ~0.16 µM, respectively, but not wild-type IDH1 or any of the examined IDH2 isoforms (IC50 > 100 ¦ÌM). AGI-5198 has good cellular activities in TS603 glioma cell line, also inhibits 2-HG production in HT1080 and U87MG cells with IC50 ~0.48 µM and IC50 ~0.07 µM, respectively. In R132H-IDH1 glioma xenografts (TS603), AGI-5198 (450 mg/kg) caused 50-60% growth inhibition with no signs of toxicity during three weeks of daily treatment, but it did not affect the growth of IDH1 wild-type glioma xenografts (TS516). Under conditions of near complete R-2HG (R-2-hydroxyglutarate) inhibition, AGI-5198 induced demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation. Blockade of mutant IDH1 impaired the growth of IDH1-mutant¡ªbut not IDH1-wild-type¡ªglioma cells without appreciable changes in genome-wide DNA methylation. AGI-5198 could serve as a very useful chemical probe to assess the biological consequences of IDH1 mutations and the potential of IDH1 inhibitor for treating IDH1 mutant tumors.

prudect name : AGI-5198 (IDH-C35) is the first highly potent and selective mutant IDH1 inhibitor that was shown to have anti-tumor efficacy and lower tumor 2‑HG (2-hydroxyglutarate) in vivo. It…

📌
0💬 read more
« Previous
1 … 839 840 841 842 843 … 931
Next »